Key facts
- This page summarizes Kelly A. Kramer's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 May 2026, 16:19.
Kelly A. Kramer - 30 Apr 2026 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- Director
- Issuer ticker
- GILD
- Reported as of
- 30 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 May 2026, 16:19:20 UTC
- Prior SEC filing
- 03 Dec 2025
- Next SEC filing
- 04 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Kim by Power of Attorney for Kelly A. Kramer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kelly A. Kramer filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 04 May 2026.
Change
- Previous filing in this sequence was filed on 03 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001629885
Primary reporting owner
Kramer Kelly A.
- Relationship
- Director
- Address
- 333 LAKESIDE DRIVE, FOSTER CITY
- Signature
- /s/ Amy Kim by Power of Attorney for Kelly A. Kramer
- Signature date
- 04 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- Shares
- +1,146
- Change %
- +6%
- Price
- $0.000000*
- Shares after
- 20,256
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,146
- Exercise price
- Footnotes
- F1, F2
GILD
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +4,884
- Change %
- Price
- $0.000000*
- Shares after
- 4,884
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,884
- Exercise price
- $130.84
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Footnote F2
100% of the restricted stock units vested immediately upon the grant date of April 30, 2026.
Footnote F3
100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.